Holleboom C A, Merkus J M, van Elferen L W, Keirse M J
Department of Obstetrics and Gynaecology, bronovo Hospital, The Hague, The Netherlands.
Br J Obstet Gynaecol. 1996 Jul;103(7):702-5. doi: 10.1111/j.1471-0528.1996.tb09841.x.
To evaluate the effect of ritodrine sustained release capsules for maintaining uterine quiescence after successful treatment of active preterm labour.
Multicentre placebo-controlled trial.
Five teaching hospitals in the Netherlands.
Women (n = 95) at less than 35 weeks of gestation in whom active preterm labour had been stopped with intravenous ritodrine.
Women received either two 40 mg ritodrine sustained release capsules (n = 50) or identical placebo capsules (n = 45) three times a day for seven days.
The proportion of women who received another course of active treatment was significantly smaller with the sustained release than with placebo (1 of 50 versus 11 of 45: P = 0.003) as was the number delivering because of preterm labour during treatment (0 of 50 versus 4 of 45: P = 0.04). There were no other significant differences between the two groups.
Maintenance treatment with ritodrine sustained release capsules after arrest of preterm labour reduces the risk of recurrences of preterm labour that necessitate treatment or precipitate delivery.
评估利托君缓释胶囊在成功治疗活动性早产之后维持子宫静息的效果。
多中心安慰剂对照试验。
荷兰的五家教学医院。
妊娠不足35周、已通过静脉注射利托君停止活动性早产的女性(n = 95)。
女性患者每天三次,每次服用两粒40毫克利托君缓释胶囊(n = 50)或相同的安慰剂胶囊(n = 45),共服用七天。
接受缓释制剂治疗的女性接受另一疗程积极治疗的比例显著低于接受安慰剂治疗的女性(50例中的1例对比45例中的11例:P = 0.003),治疗期间因早产分娩的人数也是如此(50例中的0例对比45例中的4例:P = 0.04)。两组之间无其他显著差异。
早产停止后使用利托君缓释胶囊进行维持治疗可降低需要治疗或导致分娩的早产复发风险。